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Abstract
In tropical regions, protozoan parasites can cause severe diseases with malaria, leishmaniasis, sleeping sickness, and Chagas
disease standing in the forefront. Many of the drugs currently being used to treat these diseases have been developed more
than 50 years ago and can cause severe adverse effects. Above all, resistance to existing drugs is widespread and has
become a serious problem threatening the success of control measures. In order to identify new antiprotozoal agents, more
than 600 commercial agrochemicals have been tested on the pathogens causing the above mentioned diseases. For all of
the pathogens, compounds were identified with similar or even higher activities than the currently used drugs in applied in
vitro assays. Furthermore, in vivo activity was observed for the fungicide/oomyceticide azoxystrobin, and the insecticide
hydramethylnon in the Plasmodium berghei mouse model, and for the oomyceticide zoxamide in the Trypanosoma brucei
rhodesiense STIB900 mouse model, respectively.
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Introduction
The Protozoan parasites of the genera Plasmodium spp., Leishmania
spp., Trypanosoma brucei spp. and Trypanosoma cruzi, are the disease
causative agents threatening entire populations in mainly resource
poor countries around the world.
Malaria, due to infection with Plasmodium spp., is one of the most
devastating diseases in developing countries, with 216 million cases
in 2010, causing an estimated 655,000 deaths per year [1]. Other
recent estimates assume up to 1.2 million deaths per year [2]. For
the treatment of malaria several highly active drugs are available,
like chloroquine, quinine, mefloquine, atovaquone, artesunate,
and their analogs. Thus, malaria is often not included in the list of
the neglected tropical diseases. Unfortunately, significant resistance to
almost all of these drugs has developed; even to the ‘‘last resort’’
artemisinin-derivatives, first cases of delayed clinical efficacy have
been reported [3]. Recently, large libraries from pharma
companies have been screened against protozoan parasites and
some interesting hits [4,5,6,7] have been found, especially against
malaria with the spiroindolones currently undergoing clinical
evaluation [8,9].
Most of the promising compounds in the development pipeline
are in a rather early clinical stage, so that a high failure rate is
expected [10]. Considering the rapid development of resistance,
and the challenges seen with the development of malaria vaccines
[11], a continuous refilling of research pipelines with compounds
in preclinical/clinical evaluation will be necessary, for the long term
perspective. Therefore new compounds for resistance management
would be highly desirable, even if they might not show the same
remarkably high activity levels as the recently promoted peroxide
candidates like OZ439 [12]. In addition, the global malaria agenda
has shifted from the mere control of clinical cases to malaria
elimination and eventually eradication urgently requiring transmis-
sion blocking agents [13].
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is caused by infections of T. b. rhodesiense and T. b. gambiense.
Populations living in remote rural areas of sub-Saharan Africa are at
risk of acquiring HAT. The disease burden in 2000 was estimated at
1.3 Mio DALYs (Disability-Adjusted Life Years) and the estimated
number of cases up to 70,000 in 2006 [14]. In recent years the
public health situation has improved due to increased monitoring
and chemotherapy, resulting in the decrease of reported HAT cases
to approximately 10,000 [15]. Only 4 drugs are currently registered
as HAT treatment. Pentamidine and suramin are used to treat the
hemolymphatic stage (stage 1) of the disease, while melarsoprol and
eflornithine (DFMO) are used in stage 2 of the disease when the
parasites have invaded the central nervous system (CNS) and which
is lethal if untreated. The available drugs are unsatisfactory due to
cost, toxicity, poor oral bioavailability, long treatment and lack of
efficacy. Melarsoprol is highly toxic, and up to 5% of the second
stage patients treated with melarsoprol die of a reactive encepha-
lopathy. Eflornithine treatment is expensive and logistically difficult;
it requires four daily intravenous infusions over fourteen days.
Recently the eflornithine-nifurtimox combination therapy (NECT)
was introduced [16]. The requirement of intravenous administra-
tion although reduced to a quarter of injections as compared to
monotherapy is still a limitation, with a need for new and more
easily administrable drugs.
Trypanosoma cruzi infection elicts Chagas disease and is an
important public health problem causing approximately 14,000
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deaths and 0.7 Mio DALY annually [17]. Treatment options are
limited due to toxicity of available drugs, parasite resistance, and
poor drug activity during the chronic phase of the disease.
Currently there are two medications being used to treat Chagas
disease, nifurtimox and benznidazole [18]. Severe toxicity and
long treatment requirements are associated with both drugs [19].
Therefore new medications are badly needed for treating this
disease especially in its chronic phase.
Leishmaniasis causes approximately 50,000 deaths and 2.1 Mio
DALY annually [20]. It threatens about 350 million people
around the world and 12 million people are believed to be
infected, with 1–2 million estimated new cases every year [21].
Widely used medications are still based on i.v. application of
antimony compounds like stilbogluconate, resulting in severe side
effects. More modern, but also more expensive medications are
liposomal amphotericin B, miltefosine, and paromomycin [22].
Thus new affordable and effective therapies are urgently needed
to combat these disastrous diseases. Registration requirements for
agrochemicals are in some aspects even more stringent than for
pharmaceuticals, as side effects that are tolerated for drugs against
many life threatening diseases, are not acceptable for agrochem-
icals that potentially could enter the food chain [23,24,25]. As a
consequence, all commercialized agrochemicals must go through
broad toxicological profiles including e.g. chronic and reprotox-
icological studies in different mammalian species, covering at least
part of the preclinical studies required for drug development.
Furthermore, agrochemicals are highly optimized on agrochem-
ical pest targets with often good selectivities in mammals and
excellent temperature and storage stability. Another interesting
feature of commercial agrochemicals is the very low production
cost of only a few cent/g, as the compounds are produced in
highly optimized processes on the multi-ton scale. Surprisingly,
these aspects have not led to a systematic evaluation of agrochemi-
cals for pharmacological use so far [26].
Here we present data of over 600 commercial agrochemicals




A library of over 600 compounds (for a list of CAS-numbers and
common names of the tested agrochemicals see Supporting
Information S1), that are or have been active ingredients in
commercial agrochemical products, has been compiled from the
BASF compound depository and was dissolved in DMSO stock
solutions in a concentration of 10 mg/ml. These samples were
then further diluted according to the requirements of the assays.
The structural integrity of the dissolved samples has been
confirmed subsequently by LCMS-analysis.
Bioassays
Plasmodium falciparum (Pf). P. falciparum drug-sensitive
strain NF54 was cultivated in a variation of the medium previously
described, consisting of RPMI 1640 supplemented with 0.5%
ALBUMAX II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3),
0.36 mM hypoxanthine, and 100 mg mL21 neomycin. Human
erythrocytes served as host cells. Cultures were maintained in an
atmosphere of 3% O2, 4% CO2, and 93% N2 in humidified
modular chambers at 37uC. Compounds were dissolved in
(CH3)2SO (10 mg mL
21), diluted in hypoxanthine-free culture
medium and titrated in duplicates over a 64-fold range in 96-well
plates. Infected erythrocytes (1.25% final hematocrit and 0.3%
final parasitemia) were added into the wells. After 48 h incubation,
0.5 mCi of [3H]hypoxanthine per well was added and the plates
were incubated for an additional 24 h. Parasites were harvested
onto glass-fiber filters, and radioactivity was counted using a
Betaplate liquid scintillation counter (Wallac, Zurich). The results
were recorded and expressed as a percentage of the untreated
controls. Fifty percent inhibitory concentrations (IC50) were
estimated by linear interpolation. Assays were run in duplicate
and at least repeated once. Artesunate and chloroquine were used
as positive controls.
Trypanosoma brucei rhodesiense (Tb). Trypanosoma brucei
rhodesiense strain STIB900 was isolated in 1982 from a human
patient in Tanzania and after several mouse passages cloned and
adapted to axenic culture conditions [27] Minimum Essential
Medium (50 mL) supplemented with 25 mM HEPES, 1 g L21
additional glucose, 1% MEM non-essential amino acids (1006),
0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate and 15% heat
inactivated horse serum was added to each well of a 96-well
microtiter plate. Serial drug dilutions of eleven 3-fold dilution steps
covering a range from 100 to 0.002 mg mL21 were prepared.
Then 46103 bloodstream forms of T. b. rhodesiense STIB 900 in
50 mL was added to each well and the plate incubated at 37uC
under a 5% CO2 atmosphere for 70 h. 10 mL resazurin solution
(resazurin, 12.5 mg in 100 ml double-distilled water) was then
added to each well and incubation continued for a further 2–4 h
[28]. Then the plates were read with a Spectramax Gemini XS
microplate fluorometer (Molecular Devices Cooperation, Sunny-
vale, CA, USA) using an excitation wave length of 536 nm and an
emission wave length of 588 nm. The IC50 values were calculated
by linear regression [29] from the sigmoidal dose inhibition curves.
Melarsoprol was used as positive control.
Trypanosoma cruzi (Tc). Rat skeletal myoblasts (L-6 cells)
were seeded in 96-well microtiter plates at 2000 cells/well in
100 mL RPMI 1640 medium with 10% FBS and 2 mM L-
glutamine. After 24 h, the medium was replaced by 100 mL per
well medium containing 5000 trypomastigote forms of T. cruzi
Tulahuen strain C2C4 containing the b-galactosidase (Lac Z) gene
(Buckner et al. 1996) [30]. After 48 h the medium was removed
from the wells and replaced by 100 mL fresh medium with or
without a serial drug dilution of eleven 3-fold dilution steps
covering a range from 100 to 0.002 mg mL21. After 96 h of
incubation, the plates were inspected under an inverted micro-
scope to assure growth of the controls and sterility. Then the
substrate CPRG/Nonidet (50 mL) was added to all wells. A
color reaction developed within 2–6 h and could be measured
Author Summary
Even though agrochemistry and infectious disease control
have the same principle goal - the suppression of harmful
organisms without harming human health and the
environment - there have been only very limited activities
to exploit this overlap for the development of new anti-
infectious drugs so far. In this study and for the first time,
over 600 commercial agrochemicals were systematically
screened against the infectious pathogens causing malaria,
sleeping sickness, Chagas disease and leishmaniasis. Many
highly active compounds with known low mammalian
toxicity were identified in cell based assays, and the
activity of some of them could even be confirmed in first
animal model studies. Further expansion of this concept to
other pathogens and the examination of analogues of the
identified hits, potentially available from agrochemical
companies, would allow for a very efficient source of novel
drug candidates.
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photometrically at 540 nm with a VersaMax microplate reader
(Molecular Devices Cooperation, Sunnyvale, CA, USA). The IC50
values were calculated by linear regression from the sigmoidal dose
inhibition curves. Benznidazole was used as positive control.
Leishmania donovani (Ld). Amastigotes of L. donovani strain
MHOM/ET/67/L82 were grown in axenic culture at 37uC in
SM medium [31] at pH 5.4 supplemented with 10% heat-
inactivated fetal bovine serum under an atmosphere of 5% CO2 in
air. One hundred microlitres of culture medium with 105
amastigotes from axenic culture with or without a serial drug
dilution were seeded in 96-well microtitre plates. Serial drug
dilutions of eleven 3-fold dilution steps covering a range from 100
to 0.002 mg mL21 were prepared. After 70 h of incubation the
plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions. 10 mL resazurin
solution (resazurin, 12.5 mg in 100 ml double-distilled water) [32]
were then added to each well and the plates incubated for another
2 h. Then the plates were read with a Spectramax Gemini XS
microplate fluorometer (Molecular Devices Cooperation, Sunny-
vale, CA, USA) using an excitation wave length of 536 nm and an
emission wave length of 588 nm. The IC50 values were calculated
by linear regression from the sigmoidal dose inhibition curves.
Miltefosine was used as positive control.
P. berghei in vivo model. From a donor mouse with appro-
ximately 30% parasitaemia (PbANKA-GFPCON) [33], heparinized
blood (containing 50 mL of 200 u mL21 Heparin) was taken and
diluted in physiological saline to 108 parasitized erythrocytes per
mL. Of this suspension, 0.2 mL were injected intravenously (i.v.)
into experimental groups of 3 mice, and a control group of 5 mice.
6, 24, 48 and 72 hours after infection (6 hour time point omitted
during 3 times treatment), the experimental groups were treated
with a single daily dose (p.o. or s.c.). 24 hours after the last drug
treatment (96 hours after infection), 1 mL tail blood was taken and
the parasitaemia determined with a FACScan. The difference
between the mean value of the control group and those of the
experimental groups was calculated and expressed as a percent
relative to the control group ( = activity). The survival of the animals
was monitored up to 30 days. Mice surviving for 30 days were
checked for parasitaemia by slide reading. A compound was
considered curative if the animal survived to day 30 post-infection
with no detectable parasites. All protocols and procedures were
reviewed and approved by the local veterinary authorities of the
Canton Basel-Stadt.
T. b. rhodesiense in vivo model. The STIB900 acute
mouse model mimics the first stage of the disease [34,35]. Four
female NMRI mice were used per experimental group. Each
mouse was inoculated i.p. with 104 bloodstream forms of
STIB900. Heparinized blood from a donor mouse with approx-
imately 56106 mL21 parasitaemia was suspended in PSG to
obtain a trypanosome suspension of 46104 mL21. Each mouse
was injected with 0.25 ml. Compound treatment was initiated 3
days post-infection on four consecutive days for all administration
routes (i.p., p.o.) in a volume of 10 mL kg21. Three mice served as
infected-untreated controls. They were not injected with the
vehicle alone since we have established in our labs that these
vehicles do not affect parasitaemia nor the mice. Parasitaemia was
monitored using smears of tail-snip blood twice a week after
treatment for two weeks followed by once a week until 60 days
post-infection. Mice were considered cured when there was no
parasitaemia relapse detected in the tail blood over the 60-day
observation period. Mean relapse days were determined as day of
relapse post-infection of mice. All protocols and procedures were
reviewed and approved by the local veterinary authorities of the
Canton Basel-Stadt.
Ethics statement
All work was conducted in accordance to relevant national and
international guidelines. The in vivo efficacy studies were approved
by the veterinary authorities of the Canton Basel-Stadt. The in
vivo studies were carried out under license No. 1731 and license
No. 739 of the Kantonales Veterina¨ramt, CH-4025 Basel,
Switzerland adhering to the Tierschutzverordnung from
23.04.2008 (based on the Tierschutzgesetz from 26.12.2005).
Results and Discussion
Starting with the analysis of the phylogenetic relationship of the
pests combated with agrochemicals, and the most important
tropical infectious disease pathogens as defined by WHO [36], the
close relationship of oomycetes, to which important agricultural
pathogens like potato blight or downy mildew belong, with
protozoan parasites was realized [37]. As a result, a first set of
oomyceticidal agrochemicals was tested, resulting in a number of
interesting hits. Based on this finding, over 600 commercially
available agrochemicals were selected and their activity against the
tropical disease pathogens Plasmodium falciparum, Leishmania donovani,
Trypanosoma cruzi and Trypanosoma brucei rhodensiense tested in cell
based screens.
Activity against Plasmodium falciparum
In vitro activity against Plasmodium falciparum. For 24
commercial agrochemicals sub-mM activity on P. falciparum could
be shown (Figure 1), therefore only the most active compounds will
be discussed in more detail. The standards Artesunate (LD50 rat
i.p. 352 mg/kg; LD50 p.o. not available) [38,39] and Chloroquine
in the same assay (LD50 rat p.o. 330 mg/kg) [40] exhibited an
activity of 5.7 and 17.1 nM, respectively.
Fluacrypyrim, (LD50 rat p.o. .2000 mg/kg) [41] demonstrated
the best activity against P. falciparum of all agrochemicals with an
IC50 of 8.3 nM. Fluacrypyrim is an acaricide from the group
known as the strobilurins, which is mainly used in Japan against
mites in orchards. The acaricidal mode of action is the inhibition
of respiration by binding to the Qo-site of the bc1-complex [42].
This target is also addressed by the antimalarial drug Atovaquone.
Other strobilurin-analogues have been examined before as
antimalarials [43].
Azoxystrobin (LD50 rat p.o. .5000 mg/kg), also a strobilurin,
showed activity at 15 nM. Azoxystrobin is a broadspectrum
fungicide and oomyceticide with annual sales of .1 bnJ, and
production volumes of several 1000 tons/year. It is one of the
predominant agrochemicals in the market. Azoxystrobin has also
been identified in a high throughput screening campaign of Glaxo-
SmithKline, where it showed an IC50 value of 41 nM against P.
falciparum [44]. This result has surprisingly not been mentioned in
the analysis and no follow up has been published.
Hydramethylnon (LD50 rat p.o. 1131 mg/kg), an insecticide
used in baits against ants, termites and cockroaches, showed
53 nM activity. It is also inhibiting the respiration chain, but
probably not at the Qo binding site [45].
Iminoctadine (LD50 rat p.o. 300 mg/kg), a broad spectrum
fungicide, showed 68 nM activity, with the mode of action
presumed to be interaction with cell membranes and lipid
biosynthesis. Related bisguanidines have also been examined
extensively as antiprotozoal drugs before [46].
Acequinocyl (LD50 rat p.o. .5000 mg/kg), an acaricide used
predominantly against mites in ornamentals, exhibited an IC50
value of 76 nM. It is also inhibiting the Qo-site in the bc1-complex
like atovaquone, to which it also shows some structural similarities.
Agrochemicals against Tropical Diseases
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Additional strobilurins with broadspectrum fugicidal and
oomyceticidal activity were tested including trifloxystrobin (LD50
rat p.o. .5000 mg/kg), dimoxystrobin (LD50 rat p.o. .5000 mg/
kg), picoxystrobin (LD50 rat p.o. .5000 mg/kg), and pyraox-
ystrobin (LD50 not available), resulting in IC50 values of 84, 148,
305 and 859 nM activity, respectively.
The pre-emergence herbicides from the dinitroaniline-type
including prodiamine (LD50 rat p.o. .5000 mg/kg), dinitra-
mine (LD50 rat p.o. 3000 mg/kg), and fluchloralin (LD50 rat
p.o. 1550 mg/kg), showed values of 118, 253 and 816 nM
activity, respectively. Their mode of action is the inhibition of
mitosis. Other herbicidal dinitroanilines have been shown
before to have antiplasmodial activity, but on a significantly
weaker level [47].
The plant growth regulator tetcyclacis (LD50 rat p.o. 261 mg/kg)
inhibits P450 enzymes [48] and exhibits an IC50 value of 194 nM.
Fenchlorazol-ethyl (LD50 rat p.o. .5000 mg/kg), an herbicide
safener used in cereals, showed 223 nM activity. Furthermore, the
corresponding acid, which is potentially the first metabolite of
fenchlorazol-ethyl, showed no activity in the assay. Other sub-
mM agrochemicals are fluazinam (IC50 = 258 nM), cafenstrole
(493 nM), difenthiuron (560 nM), fenamidone (641 nM) and
butamifos (816 nM).
The biocides fentin acetate (33 nM) (LD50 rat p.o. 140–278 mg/
kg), berberine (83 nM) (LD50 rat i.v. 60 mg/kg), cycloheximide
(101 nM) (LD50 rat p.o. 2 mg/kg), fentin hydroxide (408 nM) (LD50
rat p.o. 150–165 mg/kg) and thiocyclam (525 nM) (LD50 rat p.o.
370 mg/kg) which are used in agrochemistry e.g. as seed dressing,
Figure 1. In vitro activity of the top 10 most active commercial agrochemicals on P. falciparum NF54 strain. The IC50 values are the means
of two independent assays; the individual values vary by less than a factor of 2.
doi:10.1371/journal.pntd.0001805.g001
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Figure 2. Top 10 most active commercial agrochemicals on T. cruzi. The IC50 values are the means of two independent assays; the individual
values vary by less than a factor of 2.
doi:10.1371/journal.pntd.0001805.g002
Agrochemicals against Tropical Diseases
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also showed high activity against P. falciparum, but were not further
followed up due to their published high toxicity in mammalian
species.
In vivo antimalarial activity. In the P. berghei mouse
model azoxystrobin showed after 46100 mg/kg p.o. applica-
tion no significant activity using the Tween-formulated a.i.; but
using the aqueous suspension of the commercial fungicidal
formulation (200 g/l suspension concentrate) in p.o. applica-
tion, an extension of survival time from 6–7 to 10.7 days
compared to untreated control animals was achieved. With s.c.
application of the aqueous formulation a reduction of parasit-
emia by 98% compared to the untreated mice 24 hrs after last
compound application (or 96 hrs after infection) and an
extension of the survival time from 6–7 to 13.3 days was
observed. This suggests some potential for further optimization
of the delivery system.
Hydramethylnon showed with 46100 mg/kg s.c. application a
reduction of parasitemia of 87% and an extension of survival time
from 6–7 to 14 days. Furthermore, with a 46100 mg/kg p.o.
application, the parasitemia was reduced by 96% and the survival
time was increased to up to 16 days. Considering the challenging
physicochemical properties, moderate transfer factor and the non-
optimized dosing regime and formulation of hydramethylnon
there might still be some potential to reach a sufficient activity level
especially in combination therapies. This warrants further follow
up and is currently under examination.
Activity on Trypanosoma cruzi (Chagas disease)
38 agrochemicals with sub-mM activity on T. cruzi were
identified, many of which being azoles with P450-inhibiting
activity (Figure 2). P450-monoxygenases have been discussed
before as targets against T. cruzi, especially the sterol 14a-
demethylase [49].
The standard drug benznidazole (LD50 rat p.o. not available)
[50,51] has an IC50 of 1871 nM in this assay.
Ipconazole (LD50 rat p.o. 888 mg/kg), has an IC50 of 3.0 nM,
the most active agrochemical against T. cruzi. It is a fungicide used
predominantly in seed dressing. The tested material is, like the
Figure 3. Most active commercial agrochemicals on L. donovani. The IC50 values are the means of two independent assays; the individual
values vary by less than a factor of 2.
doi:10.1371/journal.pntd.0001805.g003
Agrochemicals against Tropical Diseases
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commercial material, racemic and a mixture of diastereomers,
therefore an enantiopure isomer could potentially have even
higher activity.
Difenoconazole (LD50 rat p.o. 1453 mg/kg), a broad spectrum
and systemic fungicide, showed an IC50 value of 7.4 nM. This
commercial agrochemical is again a racemic diasteromeric
Figure 4. Top 10 most active commercial agrochemicals on T. b. rhodesiense. The IC50 values are the means of two independent assays; the
individual values vary by less than a factor of 2.
doi:10.1371/journal.pntd.0001805.g004
Agrochemicals against Tropical Diseases
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mixture and could therefore also have intrinsically higher activity
as a pure isomer.
Clotrimazole (14 nM), and viniconazole [52] (26 nM), are two
azole drugs used against fungal skin infections, that have also been
discussed as agro fungicides and therefore have been tested in this
screen. As they have a complete pharmacological dossier they
might also be interesting drug candidates.
Zoxamide (LD50 rat p.o. .5000 mg/kg), a broadspectrum
oomyceticide used in fruits and vegetables, showed 27 nM activity.
It is sold and was tested as a racemate. Its mode of action against
oomycetes is the inhibition of microtubule formation.
Pyridaben (30 nM), and tolfenpyrad (55 nM), are insecticides/
acaricides inhibiting the complex 1 in the mitochondrial electron
transport chain.
A number of further azole fungicides showed activities below
100 nM including metconazole 31 nM, tebuconazole 36 nM,
bitertanol 35 nM, climbazole 55 nM, prochloraz 69 nM, hexaco-
nazole 73 nM, and fenapanil 99 nM. Further agrochemicals with
high activity in this assay were penconazole (130 nM), epoxyco-
nazole (136 nM), imazalil (148 nM), propiconazole (160 nM),
fenarimol (193 nM), fluquinconazole (199 nM), picoxystrobin
(248 nM), cyproconazole (257 nM), myclobutanil (374 nM), tetra-
conazole (478 nM), and pyrifenox (491 nM).
In spite of the excellent in vitro activity initial experiments in a T.
cruzi mouse model did so far not show in vivo efficacy for selected
hits (personal communication Nazare´ Soiro).
Activity on Leishmania donovani (Leishmaniasis)
Against L. donovani only two agrochemicals showed sub-mM
activity (Figure 3). The standard miltefosine (LD50 rat p.o.
246 mg/kg) showed in this assay an IC50 value of 250 nM.
Zoxamide (LD50 rat p.o. .5000 mg/kg) showed an IC50 of
250 nM. The oomyceticidal compound has been discussed in the
T. cruzi section.
Tolylfluanid (LD50 rat p.o. .5000 mg/kg) resulted in an IC50
value of 861 nM. It is a protective fungicide and oomyceticide
with presumed thiol conjugating activity.
Other agrochemicals with moderate activity against L. donovani
were flocumafen (2451 nM), dimoxystrobin (3248 nM), bromofe-
noxin (3839 nM), cyhexatin (4517 nM), and cyazofamid
(4988 nM).
Activity on Trypanosoma brucei rhodensiense
In vitro activity against T. b. rhodensiense. The standard
melarsoprol, an arsenate derivative (LD50 in mouse i.v. 44 mg/kg),
showed an IC50 value of 5 nM in this assay.
Seven sub-mM active agrochemicals could be identified in the T.
b. rhodensiense assay (Figure 4). The two agrochemicals thiram (IC50
12 nM), and thiolutin (IC50 9 nM) [53] are known to have rather
high cytotoxicity in cell systems, which likely interferes with this
assay.
Zoxamide (LD50 rat p.o. .5000 mg/kg) showed the highest
activity with an IC50 value of 6 nM. This oomyceticidal
compound has been discussed above. Toylfluanid (LD50 rat p.o.
.5000 mg/kg), showed an IC50 value of 52 nM, in addition to its
activity against L. donovani.
In addition to the above described antimalarial activity,
hydramethylnon (LD50 rat p.o. 1131 mg/kg), showed 663 nM
activity.
Chlorothalonil (LD50 rat p.o. .5000 mg/kg), a protective
fungicide with thiol conjugating activity, showed 688 nM activity.
Iminoctadin/guacetin (LD50 rat p.o. 360 mg/kg), showed
743 nM activity and is discussed in the P. falciparum chapter.
In vivo activity against T. b. rhodensiense. Zoxamide has
been tested in the T. b. rhodesiense mouse model for the acute phase
of human African trypanosomiasis. Zoxamide showed with
46200 mg/kg i.p. a weak activity. On day 7 post infection,
24 hours after the last treatment, no T. b. rhodesiense could be
detected; on day 10 all mice showed a relapse.
Conclusion
Due to the split of most life science companies into their agro-
and pharma branches in the 1990s, the companies active in
agrochemistry have not been involved in the recent screening
activities to identify new drugs against infectious tropical diseases,
even though agrochemicals might have a high potential to yield
interesting hits for these applications.
In this cooperation between industrial and public partners, it
was shown for several commercial agrochemicals that they are
highly active against some of the most important pathogens
of infectious tropical diseases. Interestingly as anticipated, several
of the oomyceticides (strobilurins against P. falciparum, zoxamide
against T. b. rhodesiense and L. donovani) were active against these
protozoans, but also other agrochemicals (e.g. hydramethylnon
against P. falciparum; azoles like iproconazole against T. cruzi)
showed very interesting activities. Exemplified by one of the major
commercial agrochemicals, the fungicide azoxystrobin, as well as
for the insecticide hydramethylnone, the reduction of parasitemia,
and significant life extension for P. berghei infected mice was
achieved. For zoxamide, an effect against T. brucei in the mouse
model was also demonstrated. This successful in vitro– in vivo
transfer without galenic optimization could not be taken for
granted, as these agrochemicals have not been optimized for
mammalian pharmacokinetics.
There is still a high probability that the identified hits in the end
might not be suitable for human use, as there are still several hurdles
to overcome. However, the results of this highly focussed and
relatively low input approach are more promising than could have
been hoped for. It is especially noteworthy, that the screen of less
than 700 agrochemical resulted in e.g. 24 new sub-mM hits against
P. falciparum, compared to 4 new sub-mM hit in over 2687 recently
tested commercial drugs (excluding known antimicrobial and anti-
cancer a.i.) [54,55]. This clearly demonstrates that agrochemistry
can be a very interesting and so far untapped source of new leads,
and maybe even drug candidates, against protozoal diseases.
It would also be very interesting to screen commercial
agrochemicals against the pathogens of other neglected diseases,
like schistosomes, nematodes, food borne trematodes, diarrhoeal
amoebas and also tropical bacterial pathogens, for which good
antibiotic cures are missing. These studies are still to be done.
Supporting Information
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